WO2022041233A1 - 一种用于移动终端的病原体和抗体检测系统 - Google Patents

一种用于移动终端的病原体和抗体检测系统 Download PDF

Info

Publication number
WO2022041233A1
WO2022041233A1 PCT/CN2020/112661 CN2020112661W WO2022041233A1 WO 2022041233 A1 WO2022041233 A1 WO 2022041233A1 CN 2020112661 W CN2020112661 W CN 2020112661W WO 2022041233 A1 WO2022041233 A1 WO 2022041233A1
Authority
WO
WIPO (PCT)
Prior art keywords
detection
role
pathogen
mobile terminal
subject
Prior art date
Application number
PCT/CN2020/112661
Other languages
English (en)
French (fr)
Inventor
余伟华
Original Assignee
余伟华
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 余伟华 filed Critical 余伟华
Priority to PCT/CN2020/112661 priority Critical patent/WO2022041233A1/zh
Publication of WO2022041233A1 publication Critical patent/WO2022041233A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Definitions

  • the invention relates to the technical field of medical detection, in particular to a pathogen and antibody detection system for mobile terminals.
  • the novel coronavirus pneumonia (COVID-19), which broke out at the end of 2019, caused an unprecedented crisis and has a tendency to become permanent.
  • the pneumonia caused by the new coronavirus has a certain mortality rate.
  • the virus has a strong human-to-human transmission ability and can produce a large number of patients in a short period of time.
  • Important measures to block the spread of the virus are early isolation and epidemiological tracking, which requires a digital management system for efficient collection, determination, and statistical analysis of test results.
  • the current medical system is separated from the production system of testing equipment, which cannot ensure the uniqueness and authenticity of testing equipment, nor can it guarantee the authenticity of testing personnel, the authenticity and reliability of testing results for public testing results.
  • the pathogen and antibody detection system for mobile terminals provided by the present invention can effectively solve the above problems.
  • a pathogen and antibody detection system for a mobile terminal comprising:
  • the identity creation module is used to create a unique identity for the detection device, and create an operator role or a subject role with a unique identity according to the user information;
  • the binding module is used to bind the detection equipment, operator role and subject role to this detection activity according to the detection activity to be performed;
  • the detection information processing module is used to obtain the detection results of the detection equipment, and to judge the accuracy of the detection results;
  • the intelligent mobile terminal module is used to identify the unique identification of the detection device, the operator role or the subject role, and to obtain the data of this detection activity for the operator role or the subject role.
  • the identity creation module generates an identity code corresponding to the operator role or the subject role according to the user's registration information, mobile phone verification code or LBS information.
  • the identity creation module when creating the operator role or the subject role, the identity creation module also generates one or more of a two-dimensional code corresponding to its identity code, an NFC tag, a Bluetooth identification address, and a WIFI identification address.
  • the operator role identifies the unique identification of the detection device or the subject's role through QR code scanning, NFC connection, Bluetooth or WIFI connection of the intelligent mobile terminal module, and associates the detection device or the subject's role with the current detection Activity binding.
  • the detection information processing module can acquire the detection result image information of the detection device through the camera device.
  • the detection information processing module compares the detection result image information captured by the camera device with the standard output result image information of the detection device according to the image recognition technology, so as to complete the inspection of the accuracy of the detection result.
  • the detection information processing module can also summarize the detection data of all detection activities to form corresponding map information, and the operator role or the subject role can obtain the map information through the intelligent mobile terminal module.
  • the operator role can also create an organization with a unique identity through the identity creation module.
  • an organization can also create subordinate organizations to which it is attached, and other operator roles or subject roles can join the organization or its subordinate organizations.
  • the detection device includes colloidal gold test paper.
  • the beneficial effects of the present invention are: a pathogen and antibody detection system for mobile terminals, by marking the detection equipment with a unique identification code, the authenticity of the device, reagent or test paper used as the detection equipment is guaranteed from production to detection activities, It ensures the authenticity and validity of the identity of the operator and the subject, and improves the authenticity and reliability of pathogen and antibody detection.
  • the present invention provides a pathogen and antibody detection system for a mobile terminal, comprising: an identity creation module for creating a unique identity for the detection device, and creating an operator role or an operator with the unique identity according to user information. subject's role;
  • the binding module is used to bind the detection equipment, the operator role and the subject role to this detection activity according to the detection activity to be performed;
  • the detection information processing module is used to obtain the detection results of the detection equipment, and to judge the accuracy of the detection results;
  • the intelligent mobile terminal module is used to identify the unique identification of the detection device, the operator role or the subject role, and to obtain the data of this detection activity for the operator role or the subject role.
  • the identity creation module generates an identity code corresponding to the operator's role or the subject's role according to the user's registration information, mobile phone verification code or LBS information, and also generates a QR code, NFC tag, One or more of Bluetooth identification address and WIFI identification address.
  • the operator is a legal person or a natural person.
  • the identity creation module can also generate a unique identity for each detection device through HASH, MD5 and other unique coding technologies based on the detection device information and the authoritative timestamp requested during production, and generate the corresponding QR code and NFC tag. , Bluetooth identification address, WIFI identification address, etc.
  • the operator role identifies the unique identification of the detection device or the subject's role through QR code scanning, NFC connection, Bluetooth or WIFI connection of the intelligent mobile terminal module, and associates the detection device or the subject's role with the current detection. Activity binding.
  • the detection results of the detection equipment can be imaged, and the detection equipment includes colloidal gold test paper.
  • the standard output result image is compared to know whether the detection result is accurate. Therefore, in the embodiment of the present invention, the detection information processing module uses the detection device to detect the role of the subject according to the usage requirements, and after the detection device completes the detection, the detection device is detected by an external or built-in camera device. The result is photographed, thereby acquiring image information of the detection result of the detection device. Then, the detection information processing module compares the detection result image information captured by the camera device with the standard output result image information of the detection device according to the image recognition technology, so as to complete the inspection of the accuracy of the detection result. The detection information processing module also judges the integrity and validity of the detection activity data. According to the inspection requirements of the testing equipment, the test strip or equipment that has completed the test can be rejected for secondary use.
  • the operator role also has the ability to create an organization, and an organization with a unique identity can be created through the identity creation module.
  • the organization includes 4 levels, and each parent organization can create 100 subordinate organizations; that is, when the first level organization created is 1, the second level includes 1001 this level organization, and the third level includes 1002 this level organization Organization, the fourth level includes 100 3 organizations at this level.
  • the four-level organization is used to cover large-scale detection scenarios in hospitals, communities, and cities; at the same time, a corresponding unique identification code is set for each organization.
  • the operator role can assign members to the organization, or invite other system users to join the organization, and manage the inspection activities through the organization.
  • the detection result output module and the detection information processing module can also summarize the detection data of all detection activities to form corresponding map information, and the operator role or the subject role can obtain the map information through the intelligent mobile terminal module.
  • the operator role or the subject role can quickly view the current test result overview and the spread of pathogens and antibodies; at the same time, operators can conduct combined queries by multiple dimensions of organization, member, time, pathogen and antibody type, test results, and geographic location , the viewing of different data can be restricted according to the identity permissions of the operator role.
  • the system of the present invention is embodied in the form of software or APP.
  • Users can complete the role registration through their own smart mobile terminals, and choose to be an operator role or a subject role according to their functions.
  • the detection device is attached with a unique identification when it is produced.
  • the operator role needs to be wirelessly connected to the detection device, that is, to bind the operator's identity to the detection device's identity and demarcate it as the operator.
  • the subject role it also needs to realize a wireless connection with the detection device, that is, bind its own identification with the identification of the detection device, and demarcate it as the subject side.
  • the operator role samples the subjects according to the requirements, uses the testing equipment for testing, takes pictures of the testing results, and then uploads all the data information of this testing activity to the server.
  • the data of this testing activity includes the photographed testing results.
  • Image information, operator role identity information, subject role identity information and detection equipment related information are examples of the testing equipment for testing.
  • the system will also recognize the test result image uploaded to the server, and judge the validity of the test result, and at the same time judge the integrity and validity of the entire submitted data; other operators of the organization or system can detect the submitted data. Check whether the data is accurate, and correct the test results; all test data are summarized on the data page and presented to users in the form of maps. Users can quickly view the current test results overview and the spread of pathogens and antibodies.
  • the invention combines personal intelligent mobile equipment with hardware such as medical colloidal gold test paper through a software system, so as to achieve rapid digital fixation, management, grid connection and monitoring of medical data.
  • Generate a unique ID for each testing device, operator, and subject and establish contact through personal mobile communication, smart phones, tablet computers, smart watches, smart bracelets and other wearable hardware devices to identify the ID.
  • Support QR code, NFC, Bluetooth, WIFI and other connection methods At the same time, it can realize on-site rapid research and report whether there is a specific pathogen and antibody infection in an individual and the copy number of the infectious pathogen and antibody. Describe, dynamically change and manage the infection situation of individuals, groups, and organizations in specific space and time dimensions.
  • sample reaction tube at the bottom of the sample holder with a width of 12 mm and a height of 45 mm, and then close and fasten the sample holder.
  • the connection between the sample reaction tube and the sample holder is 4 mm.
  • the colloidal gold detection box is 27 mm wide and 65 mm high, and is divided into a 15 mm wide reaction chamber with a closed top and a 12 mm wide sample placement chamber with an open top.
  • the reaction chamber and the placement chamber are spaced apart with a 5 mm gap at the bottom of the space.
  • the reaction chamber of the colloidal gold detection box contains a 5 mm wide reaction test paper. Below the test paper is a 15 mm sample pad. There is a second test paper detection line 15 mm above the sample pad, and a first test paper detection line 20 mm above the sample pad. Line, there is a test strip control line 25 mm above the sample pad, of which 2 detection lines are used to detect virus positive, 1 detection line is used to detect virus negative, and the control line is used to detect the validity of the test strip.
  • the top buckle is pressed down and locked, and the entire colloidal gold detection box is completely closed.
  • a piercing object at the bottom of the placement chamber of the detection box, which is used to pierce the bag-shaped sample container. After the sample reaction tube is pierced, the sample mixture flows into the colloidal gold reaction chamber, and then waits for the colloidal gold to develop color for 3 minutes.
  • the reaction changes of the test strip can be photographed through personal intelligent mobile communication devices, and the software system captures, judges, reports and transmits data and manages it.
  • the device After the reaction, the device shall be disposed of harmlessly according to the specifications.
  • the colloidal gold test paper used above is used to detect the pathogen itself, and among them, it should also be noted that magnetic pads and magnetic materials can be added to the test paper to simultaneously detect the antibody content in the sample and improve the detection reliability; or Use test strips that detect antibodies to directly detect the antibody content in the sample, so as to determine the current disease condition or immunity level of the human body. When detecting antibodies, it is necessary to put the test strip into other magnetic detection equipment, read the data and synchronize it to the test results through the network, so that users can obtain relevant test information and test results through the system.
  • the present invention provides a pathogen and antibody detection system for mobile terminals.
  • the detection equipment, reagents or test strips used as detection equipment are guaranteed to be safe from production to detection activities. Authenticity, and ensure the authenticity and validity of the identity of the operator and the subject, so that the detection equipment can establish a direct connection with the tester or the testee through intelligent communication terminals and wearable smart devices.
  • it also solves the statistics and management problems of loose large-scale social organization testing data, improves the validity and execution efficiency of testing results through image recognition technology and personnel review, and can quickly and intuitively view pathogens and antibodies in various organizations through data presentation.
  • the present invention can support large-scale, rapid and effective detection of pathogens and antibodies, has simple process, convenient deployment, and improves the accuracy and detection efficiency of pathogen and antibody detection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Theoretical Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

一种用于移动终端的病原体和抗体检测系统，通过为检测设备标注唯一标识码，保证了作为检测设备的装置、试剂或试纸从生产到检测活动时的真实性，并确保了操作者与受检者的身份真实有效性，提高病原体和抗体检测的真实性和可靠性。

Description

一种用于移动终端的病原体和抗体检测系统 技术领域
本发明涉及医用检测技术领域，具体为一种用于移动终端的病原体和抗体检测系统。
背景技术
2019年底爆发的新冠状肺炎(COVID-19)，引发空前危机，并且已经有永久化趋势，该肺炎由新冠状病毒引起，有一定的死亡率，同时该病毒具备很强的人传人能力，可短期产生大量病人。阻断病毒传播的重要措施就是早期隔离和流行病学追踪，这需要进行高效的检测结果采集、判定、统计分析的数字化管理系统。
当前的医疗系统与检测设备生产系统分离，无法确保检测设备的唯一性和真实性，对于面向公众的检测结果，也不能保证检测者的真实性、检测结果的真实性和可靠程度。
发明内容
(一)解决的技术问题
本发明提供的一种用于移动终端的病原体和抗体检测系统，可有效解决上述问题。
(二)技术方案
为实现上述目的，本发明提供如下技术方案：一种用于移动终端的病原体和抗体检测系统，包括：
身份创建模块，用于为检测设备创建唯一性身份标识，和根据用户信息创建带有唯一性身份标识的操作者角色或受检者角色；
绑定模块，用于根据待进行的检测活动，使检测设备、操作者角色和受检 者角色与本次检测活动绑定；
检测信息处理模块，用于获取检测设备的检测结果，并对检测结果的准确性进行判断；
智能移动终端模块，用于识别检测设备、操作者角色或受检者角色的唯一性身份标识，并且用于为操作者角色或受检者角色获取本次检测活动的数据。
优选地，身份创建模块根据用户的注册信息、手机验证码或LBS信息，生成对应操作者角色或受检者角色的身份标识码。
优选地，身份创建模块创建操作者角色或受检者角色时，还生成对应其身份标识码的二维码、NFC标签、蓝牙识别地址、WIFI识别地址中的一种或几种。
优选地，操作者角色通过智能移动终端模块的二维码扫描、NFC连接、蓝牙或WIFI连接识别检测设备或受检者角色的唯一性身份标识，将检测设备或受检者角色与本次检测活动绑定。
优选地，检测信息处理模块可通过摄像设备获取检测设备的检测结果图像信息。
优选地，检测信息处理模块根据图像识别技术，对摄像设备拍摄的检测结果图像信息和检测设备的标准输出结果图像信息进行比较，以完成对检测结果的准确性的检验。
优选地，检测信息处理模块还可将所有检测活动的检测数据进行汇总，并形成对应的地图信息，操作者角色或受检者角色可通过智能移动终端模块获取该地图信息。
优选地，操作者角色还可通过身份创建模块创建具有唯一性身份标识的组织。
优选地，组织还可创建其附属的下级组织，其他的操作者角色或受检者角 色可加入组织或其下级组织。
优选地，检测设备包括胶体金试纸。
有益效果
本发明的有益效果是：一种用于移动终端的病原体和抗体检测系统，通过为检测设备标注唯一标识码，保证了作为检测设备的装置、试剂或试纸从生产到检测活动时的真实性，并确保了操作者与受检者的身份真实有效性，提高病原体和抗体检测的真实性和可靠性。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明提供了一种用于移动终端的病原体和抗体检测系统，包括：身份创建模块，用于为检测设备创建唯一性身份标识，和根据用户信息创建带有唯一性身份标识的操作者角色或受检者角色；
绑定模块，用于根据待进行的检测活动，使检测设备、操作者角色和受检者角色与本次检测活动绑定；
检测信息处理模块，用于获取检测设备的检测结果，并对检测结果的准确性进行判断；
智能移动终端模块，用于识别检测设备、操作者角色或受检者角色的唯一性身份标识，并且用于为操作者角色或受检者角色获取本次检测活动的数据。
具体的，身份创建模块根据用户的注册信息、手机验证码或LBS信息，生成对应操作者角色或受检者角色的身份标识码，同时还生成对应角色身份标识 码的二维码、NFC标签、蓝牙识别地址、WIFI识别地址中的一种或几种。其中，操作者为法人或自然人。身份创建模块还可基于检测设备信息和其生产时请求的权威时间戳，再通过HASH、MD5等唯一编码技术为每一个检测设备生成唯一性身份标识，并生成标识对应的二维码、NFC标签、蓝牙识别地址、WIFI识别地址等。
具体的，操作者角色通过智能移动终端模块的二维码扫描、NFC连接、蓝牙或WIFI连接识别检测设备或受检者角色的唯一性身份标识，将检测设备或受检者角色与本次检测活动绑定。
进一步的，本发明的实施例中，检测设备的检测结果可进行图像化，检测设备包括有胶体金试纸，由于胶体金试纸的检测结果可以进行图像化，因此通过将检测结果图像与胶体金的标准输出结果图像进行对比，可获知检测结果是否准确。故本发明的实施例中，检测信息处理模块在所述受检者角色按使用要求利用检测设备进行检测，并在检测设备完成检测后，通过外接的或自带的摄像设备对检测设备的检测结果进行拍摄，从而获取检测设备检测结果的图像信息。之后检测信息处理模块根据图像识别技术，对摄像设备拍摄的检测结果图像信息和检测设备的标准输出结果图像信息进行比较，以完成对检测结果的准确性的检验。检测信息处理模块还会判断检测活动数据的完整性、有效性。根据检测设备的检验要求，已经完成检测的试纸或设备可拒绝二次使用。
进一步的，操作者角色还具有创建组织的能力，可通过身份创建模块创建具有唯一性身份标识的组织。组织包括4个层级，每个上级组织可创建100个下级组织；即创建的第一层级组织是1个时，其第二层级包括100 1个本级组织，第三层级包括100 2个本级组织，第四层级包括100 3个本级组织。四级组织用以 涵盖医院、社区、城市大规模检测场景；同时针对每一组织设置对应的唯一性身份标识码。操作者角色可以为组织分配成员，也可以邀请其他系统用户加入组织，通过组织来管理各检测活动。
其中，检测结果输出模块检测信息处理模块还可将所有检测活动的检测数据进行汇总，并形成对应的地图信息，操作者角色或受检者角色可通过智能移动终端模块获取该地图信息。操作者角色或受检者角色可快速查看当前的检测结果概况和病原体和抗体传播情况；同时操作者可通过组织、成员、时间、病原体和抗体类型、检测结果、地理位置多个维度进行组合查询，可根据操作者角色的身份权限对不同数据限制查看。
在具体实施过程中，本发明的系统以软件或APP形式体现。用户可通过自身的智能移动终端完成角色注册，根据其职能选择成为操作者角色或受检者角色。检测设备在其生产时即被附带唯一性身份标识，在进行检测活动时，操作者角色需要与检测设备实现无线连接，即将操作者的标识与检测设备的标识绑定，标定为操作者一方。受检者角色在被检测时，也需要与检测设备实现无线连接，即将自己的标识与检测设备的标识绑定，标定为受检者一方。操作者角色根据要求对受检者进行采样，并使用检测设备进行检测，并对检测结果拍照，再将本次检测活动的所有数据信息上传至服务器，本次检测活动的数据包括拍摄的检测结果图像信息、操作者角色身份信息、受检者角色身份信息和检测设备相关信息。
而该系统还会基于图像识别技术，对上传至服务器的检测结果图像进行识别，并判断检测结果有效性，同时判断整个提交数据的完整性、有效性；组织或系统的其他操作者可以检测提交数据是否准确，并对检测结果进行更正；所有检测数据，汇总在数据页面，通过地图的形式向用户呈现，用户能够快速查 看当前的检测结果概况和病原体和抗体传播情况。
本发明通过软件系统将个人智能移动设备与医学胶体金试纸等硬件结合，达到快速医学数据数字化固定、管理、并网和监控。为每一个检测设备、操作者、受检者生成唯一身份标识，并可以通过个人移动通讯智能手机、平板电脑、智能手表、智能手环等穿戴式硬件装置识别标识，建立联系。支持二维码、NFC、蓝牙、WIFI等多种连接方式。同时可实现现场快速研判报告个人是否存在特定病原体和抗体感染和感染病原体和抗体的拷贝数。对特定空间、时间维度的个人、人群、组织机构感染情况描述，动态变化和管理。检测罹患个人或者人群病原体和抗体拷贝数对治疗的反应，将数据传至医疗或者预防机构实体，同时可实现流行病学追踪病原体和抗体感染者或者群体，绘制时间、空间分布图。通过本发明的系统，可至少同时捕捉、处理胶体金试纸条2条条带，对应病原体和抗体的多重位点或者多重病原体和抗体的检测，提高病原体和抗体检测的敏感性和帮助多重病原体和抗体的鉴别诊断。
以下以新冠病毒检测为例进行说明：
使用采集50-100微升个人唾液、鼻或咽拭纸采样品，加入病毒裂解液按1：1混合，置于数字化干浴加热盒，90摄氏度放置20分钟，并冷却到室温。
取5微升上述处理样品，加入逆转录/等温扩增体系管后置于置于数字化干浴加热盒，42摄氏度放置20分钟。
将样本反应管放入在12毫米宽、45毫米高的样本夹底部，放入后关闭扣紧样本夹，样本反应管与样本夹紧相连部分为4毫米。
检测胶体金检测盒宽27毫米、高65毫米，分为顶端封闭的15毫米宽反应室和顶端开口12毫米宽样本放置室，反应室和放置室中间隔开，间隔底部有5毫米空隙。
检测胶体金检测盒的反应室内含5毫米宽的反应试纸，试纸下方为15毫米样品垫，样品垫上方15毫米处有第二条试纸检测线，样品垫上方20毫米处有第一条试纸检测线，样品垫上方25毫米处有试纸控制线，其中2条检测线显色用于检测病毒阳性，1条检测线显色用于检测病毒阴性，控制线显色用于检测试纸的有效性。
带有样本反应管的样本夹放置在胶体金检测盒的样本放置室内后，顶部卡扣下压后锁紧，整个检胶体金检测盒处于完全封闭状态。
检测盒的放置室底部有刺装物，用于刺穿袋状样本容器，样本反应管刺穿后，样本混合液流入胶体金反应室，然后等待胶体金显色3分钟。
试纸的反应变化可以通过个人智能移动通讯设备拍摄，软件系统捕捉、研判、报告和传输数据并管理。
反应后装置按规范无害处置。
上述所使用的胶体金试纸，是用于检测病原体本身，而其中，还需要注意的是，可在试纸上增加磁性垫及磁性材料，以同时检测样本中的抗体含量，提高检测可靠性；或改用检测抗体的试纸，以直接检测样本中的抗体含量，从而测定人体当前的病况或免疫程度。检测抗体时，需要将试纸放入其他磁性检测设备，读取数据并通过网络同步到检测结果中，从而用户可通过该系统获取相关的检测信息和检测结果。
区别于现有技术，本发明提供了一种用于移动终端的病原体和抗体检测系统，通过为检测设备标注唯一标识码，保证了作为检测设备的装置、试剂或试纸从生产到检测活动时的真实性，并确保了操作者、受检者的身份真实有效性，让检测设备通过智能通讯终端、可穿戴智能设备与检测者或被检测者建立直接的连接。同时还解决了松散的大型社会组织检测数据的统计和管理问题，通过 图像识别技术和人员审核提高了检测结果判定的有效性和执行效率，通过数据呈现，快速直观查看各类组织的病原体和抗体传播时空分布情况。本发明能够支撑大范围、快速、有效的病原体和抗体检测，流程简单，部署便捷，提升病原体和抗体检测的准确性和检测效率。

Claims (10)

  1. 一种用于移动终端的病原体和抗体检测系统，其特征在于，包括：
    检测设备，用于检测病原体和抗体；
    身份创建模块，用于为检测设备创建唯一性身份标识，和根据用户信息创建带有唯一性身份标识的操作者角色或受检者角色；
    绑定模块，用于根据待进行的检测活动，使所述检测设备、操作者角色和受检者角色与本次检测活动绑定；
    检测信息处理模块，用于获取检测设备的检测结果，并对检测结果的准确性进行判断；
    智能移动终端模块，用于识别检测设备、操作者角色或受检者角色的唯一性身份标识，并且用于为所述操作者角色或受检者角色获取本次检测活动的数据。
  2. 根据权利要求1所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述身份创建模块根据用户的注册信息、手机验证码或LBS信息，生成对应所述操作者角色或受检者角色的身份标识码。
  3. 根据权利要求2所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，身份创建模块创建操作者角色或受检者角色时，还生成对应其身份标识码的二维码、NFC标签、蓝牙识别地址、WIFI识别地址中的一种或几种。
  4. 根据权利要求3所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述操作者角色通过智能移动终端模块的二维码扫描、NFC连接、蓝牙或WIFI连接识别检测设备或受检者角色的唯一性身份标识，将检测设备或受检者角色与本次检测活动绑定。
  5. 根据权利要求1所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述检测信息处理模块可通过摄像设备获取检测设备的检测结果图像 信息。
  6. 根据权利要求5所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述检测信息处理模块根据图像识别技术，对所述摄像设备拍摄的检测结果图像信息和检测设备的标准输出结果图像信息进行比较，以完成对检测结果的准确性的检验。
  7. 根据权利要求1所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述检测信息处理模块还可将所有检测活动的检测数据进行汇总，并形成对应的地图信息，所述操作者角色或受检者角色可通过智能移动终端模块获取该地图信息。
  8. 根据权利要求1所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述操作者角色还可通过身份创建模块创建具有唯一性身份标识的组织。
  9. 根据权利要求8所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述组织还可创建其附属的下级组织，其他的操作者角色或受检者角色可加入所述组织或其下级组织。
  10. 根据权利要求1所述的一种用于移动终端的病原体和抗体检测系统，其特征在于，所述检测设备包括胶体金试纸。
PCT/CN2020/112661 2020-08-31 2020-08-31 一种用于移动终端的病原体和抗体检测系统 WO2022041233A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/112661 WO2022041233A1 (zh) 2020-08-31 2020-08-31 一种用于移动终端的病原体和抗体检测系统

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/112661 WO2022041233A1 (zh) 2020-08-31 2020-08-31 一种用于移动终端的病原体和抗体检测系统

Publications (1)

Publication Number Publication Date
WO2022041233A1 true WO2022041233A1 (zh) 2022-03-03

Family

ID=80354328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/112661 WO2022041233A1 (zh) 2020-08-31 2020-08-31 一种用于移动终端的病原体和抗体检测系统

Country Status (1)

Country Link
WO (1) WO2022041233A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115096884A (zh) * 2022-05-30 2022-09-23 上海许晟科技有限公司 一种智能试剂检测的系统及方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127639A1 (en) * 2014-02-28 2015-09-03 Empire Technology Development Llc Systems and methods for determining concentration of a component in a fluid sample
CN106302944A (zh) * 2015-05-12 2017-01-04 联想移动通信科技有限公司 一种识别移动终端的方法及装置
CN106444683A (zh) * 2016-11-24 2017-02-22 德析科技成都有限公司 检测过程或生产过程的监管系统及方法
CN106645706A (zh) * 2015-12-29 2017-05-10 江苏戴格诺思生物技术有限公司 一种移动终端定量分析胶体金检测试剂的方法
CN107192825A (zh) * 2017-07-31 2017-09-22 重庆微奥云生物技术有限公司 一种病毒抗体检测系统及方法
CN109309572A (zh) * 2017-07-28 2019-02-05 陕西省数字证书认证中心股份有限公司 基于移动终端数字证书的统一身份认证方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127639A1 (en) * 2014-02-28 2015-09-03 Empire Technology Development Llc Systems and methods for determining concentration of a component in a fluid sample
CN106302944A (zh) * 2015-05-12 2017-01-04 联想移动通信科技有限公司 一种识别移动终端的方法及装置
CN106645706A (zh) * 2015-12-29 2017-05-10 江苏戴格诺思生物技术有限公司 一种移动终端定量分析胶体金检测试剂的方法
CN106444683A (zh) * 2016-11-24 2017-02-22 德析科技成都有限公司 检测过程或生产过程的监管系统及方法
CN109309572A (zh) * 2017-07-28 2019-02-05 陕西省数字证书认证中心股份有限公司 基于移动终端数字证书的统一身份认证方法
CN107192825A (zh) * 2017-07-31 2017-09-22 重庆微奥云生物技术有限公司 一种病毒抗体检测系统及方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SPINAZZE PIER, BOTTLE ALEX, CAR JOSIP: "Digital Health Sensing for Personalized Dermatology", SENSORS, vol. 19, no. 15, pages 3426, XP055903902, DOI: 10.3390/s19153426 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115096884A (zh) * 2022-05-30 2022-09-23 上海许晟科技有限公司 一种智能试剂检测的系统及方法

Similar Documents

Publication Publication Date Title
CN111999288A (zh) 一种用于移动终端的病原体和抗体检测系统
WO2021227791A1 (zh) 安全检测设备、方法及计算机可读存储介质
Anne et al. Feasibility and acceptability of an iris biometric system for unique patient identification in routine HIV services in Kenya
CN107680682A (zh) 基于微信平台的慢性非传染性疾病队列研究人群随访方法
JP2021114338A (ja) 業務活動分析装置、業務活動分析方法、及びプログラム。
CN102429637A (zh) 移动终端虹膜检测方法及移动终端
WO2022041233A1 (zh) 一种用于移动终端的病原体和抗体检测系统
WO2018223541A1 (zh) 基于条码扫描的临床检验报告审核系统及方法
CN104622448A (zh) 一种用于电子血压计的数据采集与管理系统及方法
Sutcliffe et al. Point-of-care p24 antigen detection for early infant diagnosis of HIV infection: cross-sectional and longitudinal studies in Zambia
US10340032B2 (en) Rapidly configurable drug detection system with enhanced confidentiality
Stanimirovic et al. Introduction of the EU digital COVID certificate in Slovenia: technological and process aspects
CN111311468A (zh) 人体温度采集处理方法及系统
Mudanyali et al. Smart rapid diagnostics test reader running on a cell-phone for real-time mapping of epidemics
US11049242B2 (en) Portable and rapid screening in vitro detection system
KR102544459B1 (ko) 일회용 진단키트의 검사결과 인증 기반 입장 통제 방법
US20240020940A1 (en) Automatic identification method, apparatus and device for detection results of immunoreagent card
WO2022163032A1 (ja) 抗原検査端末機及びそれを用いたオンライン感染検査システム
US20210379580A1 (en) Easily deployed lateral flow test instrument and management system for antigen detection in high throughput test centers
Dzobo et al. Limited syphilis testing for key populations in Zimbabwe: A silent public health threat
CN203224496U (zh) 锂电供电的储存单个人体的艾滋病信息的rfid系统
Singh et al. Cost Effective IoT-RFID Attendance Database Management System using ESP8266
CN209059268U (zh) 样本采集枪
US20220395838A1 (en) Device and method for detection of pathogens
CN114778835A (zh) 一种使用移动终端筛查病毒的检测系统和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20950902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20950902

Country of ref document: EP

Kind code of ref document: A1